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In recent years, increasing numbers of people have been choosing herbal medicines or products to improve their health conditions,
either alone or in combination with others. Herbs are staging a comeback and herbal “renaissance” occurs all over the world.
According to the World Health Organization, 75% of the world’s populations are using herbs for basic healthcare needs. Since
the dawn of mankind, in fact, the use of herbs/plants has offered an effective medicine for the treatment of illnesses. Moreover,
many conventional/pharmaceutical drugs are derived directly from both nature and traditional remedies distributed around the
world. Up to now, the practice of herbal medicine entails the use of more than 53,000 species, and a number of these are facing the
threat of extinction due to overexploitation. This paper aims to provide a review of the history and status quo of Chinese, Indian,
and Arabic herbal medicines in terms of their significant contribution to the health promotion in present-day over-populated and
aging societies. Attention will be focused on the depletion of plant resources on earth in meeting the increasing demand for herbs.

1. Introduction
Herbalism is a traditional medicinal or folk medicine practice
based on the use of plants and plant extracts. Herbs/plants,
the major component of traditional materia medica in the
world, are of the main forms of life on earth. It is estimated
that there are about 350,000 species of existing plants (including seed plants, bryophytes, and ferns), among which 287,655
species have been identified as of 2004 [1]. Herbal medicine
(HM), also called botanical medicine, phytomedicine, or
phytotherapy, refers to herbs, herbal materials, herbal preparations, and finished herbal products that contain parts of
plants or other materials as active ingredients [2]. The plant

parts used in herbal therapy include seeds, berries, roots,
leaves, fruits, bark, flowers, or even the whole plants. Man was
mainly dependent on crude botanical material for medical
needs to retain vitality and cure diseases [3] prior to the
introduction of aspirin derived from Spiraea ulmaria which
was already prescribed for fever and swelling in Egyptian
papyri and recommended by the Greek Hippocrates for pain
and fever.
Although written records about medicinal plants dated
back at least 5,000 years to the Sumerians, who described
well-established medicinal uses for such plants as laurel,
caraway, and thyme [4], archeological studies have shown
that the practice of herbal medicine dates as far back as
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60,000 years ago in Iraq and 8,000 years ago in China [5,
6]. With the advent of western medicine (or “conventional”
medicine) over the past century, herbal medicine has been
challenged by practitioners of mainstream medicine because
of the lack of scientific evidence in the context of contemporary medicine, despite its long history of effective use.
Interestingly, things change with time. In recent years, there
has been a resurgence of the use of herbs due to the side
effects of chemical drugs, lack of curative modern therapies
for several chronic diseases, and microbial resistance, as well
as the unprecedented investment in pharmaceutical research
and development (R&D) [7]. For example, only about 1,200
new drugs have been approved by the US Food and Drug
Administration (FDA) since 1950 [8]. As a result, the use of
herbs and herbal products for health purposes has increased
in popularity worldwide over the past 40 years, in both the
developing and the industrialized countries [9]. Moreover,
global pharmaceutical companies armed with modern science/technology and ideas have begun to rediscover herbs as
a potential source of new drug candidates and renewed their
strategies in favor of natural product drug development and
discovery [10–13].
Nowadays, many practitioners of “conventional”
medicine do not hesitate to recommend herbs, herbal
products, or complementary and alternative medicine
(CAM) therapy to their patients for the effective treatment
of certain diseases [14, 15]. A survey in 2007 indicated that
about 40% of adults and 11% of children used CAM therapy
(CAMT), and among the adult users, white and black adults
constituted 43.1% and 25.5%, respectively [16]. In addition,
CAM and herbal medicines are more commonly used by
people with higher levels of education and income [17, 18].
In this context, a 2012 study indicated that the use of CAM
significantly correlated with higher education level, with a
trend towards greater use in younger patients with breast
cancer [19]. Although at present, we do not fully understand
the exact facts and mechanisms underlying most traditional
remedies and/or how they prevent disease that does not affect
the enthusiasm of the public to accept CAM/CAMT [20].
Although there is a wide variety of CAM and CAMT around
the world, they can all be divided into two main categories,
namely, drug-based CAM/CAMT and non-drug-based
CAM/CAMT [21].
Our earlier endeavors, which focused on discussing
the current research and development of Chinese herbal
medicine (CHM), and the trend in drug discovery, as well
as a variety of CAM, aimed to promote the utilization of
natural and traditional resources for contemporary health
care, including food/diet therapy [7, 21–24]. As a continuing
effort, the current paper will give an overview on herbal
medicine from China, India, and Arabia, which are the three
most influential traditional medicine systems to improve
public health problems.

2. Chinese Herbal Medicine (CHM)
In ancient Chinese times “medicine” (traditional Chinese
medicine, TCM, e.g., Zhong-Yi in Chinese) and “pharmacy”
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(CHM, e.g., Zhong-Yao in Chinese) were already described as
distinct disciplines. More than 85% of Chinese materia medica (CMM) originates from plants, but animal parts/insects,
minerals, and crude synthetic compounds are also prescribed
by TCM practitioners. In addition, the term “CHM” also
encompasses a number of ethnic herbal medicines and folk
medicines in China.
2.1. Literature Overview of CHM. CHM is traditionally one
of the most important modalities utilized in TCM. It has
an extremely valuable, rich, lengthy, and extensive treatment
history. CHM was firstly described by a legendary figure
called Shen-Nong, who is said to have lived from 2737 BCE
to 2697 BCE, nearly 5,000 years ago [25, 26]. It is said
that Shen-Nong, by tasting hundreds of herbs on one day,
found more than 70 herbs that had medicinal value, selected
those that were suitable as remedies, and described their
properties [27]. As a result of his efforts, numerous herbs
(“herbal” medicine) became routinely used for health care
in ancient China [28]. Shen-Nong-Ben-Cao-Jing, the first
known user guide to CHM, was written by authors who lived
during the period immediately following the fall of the Han
dynasty (202 BCE–220 CE). The compendium documented
365 Chinese herbal preparations, including 252 kinds of plant
parts, 67 kinds of animal parts, and 46 kinds of minerals for
medication, and it also described their therapeutic effects.
Prior to the time of Shen-Nong-Ben-Cao-Jing, some
ancient Chinese scripts, such as Shang-Shu, Shi-Jing (The
book of songs), Shan-Hai-Jing, Zhou-Li, Li-Ji (The book of
rites), and Zuo-Zhuan, recorded the use of herbal remedies.
Shi-Jing, which first recorded the use of herbal remedies,
illustrated not only the therapeutic effects of the herbs,
but also the places where the herbs were grown and their
harvesting season. It recorded 170 kinds of CHMs, including
80 plant species and 90 insect species [29]. Shan-Hai-Jing,
the oldest Chinese book dealing with geography, recorded
9 species of plants with food value, 45 species of plants
with medicinal value, 6 plants with some kind of efficacy,
6 plants poisonous to animals and pests, 6 species of plants
with mood-elevating effects, 6 plants with health-promoting
properties, 19 species of plants for the treatment of diseases,
and 2 plants that are poisonous for humans [30].
More than 240 herbal drugs and 52 prescriptions were
described in the book named 52 Bing-Fang (Recipes for 52
Ailments), which was unearthed in an ancient tomb (MaWang-Dui) in China [31]. Xin-Xiu-Ben-Cao (Newly revised
materia medica), which was promulgated in 659 CE and
recorded 850 kinds of herbal drugs, was the first pharmacopoeia in China, even in the world [32]. Oracle bone, a
form of divination in ancient China, recorded more than 60
kinds of plants and animals, but they were not described as
medication.
The epic book of materia medica in TCM history, BenCao-Gang-Mu (Compendium of Materia Medica) written by
Li Shi-Zhen (1528–1593), was published in 1596 in China.
This book recorded 1,892 kinds of herbal medicines and
11,096 herbal formulae. After Charles Darwin (1809–1882)
had read the book, he stated that The Compendium of Materia
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Table 1: Some important texts in the historical developmental process of Chinese materia medica [33, 34].
Lectures
52 Bing-Fang
Shen-Nong-Ben-Cao-Jing
Xin-Xiou-Ben-Cao
Zheng-Lei-Ben-Cao
Ben-Cao-Gang-Mu
Znong-Yao-Da-Ci-Dian
Zhong-Hua-Ben-Cao
Chinese Pharmacopoeia

Issued date
200 BCE
202 BCE–220
659
1082
1596
1977
1999
2010

Total
247
365
850
1,746
1,892
5,767
8,980
2,165

Plant
115
252
635
1,151
1,094
4,773
7,815
680

Medica was the encyclopedia of 16th century in China. This
book was later translated into different languages, including
Japanese, Korean, English, French, Russian, and Latin, and it
has become a major historical reference on CMM.
The founding of China has brought about a hitherto
unprecedented development of CHM in Chinese history. The
holistic and systematic development of CHM has resulted
in an increase in the number of approved CHMs. ZhongHua-Ben-Cao, the most authoritative Chinese book with a
complete record of CMM issued in 1999, lists 8,980 kinds
of CHMs that are divided into 34 volumes and summarizes
the contemporary research of Chinese medicine with modern
science and technology. Zhong-Yao-Da-Ci-Dian (a dictionary
of traditional Chinese medicine), published in 1997, recorded
5,767 CHMs; when it was reprinted in 2006, the number of
CHMs had increased to 6,008. The Chinese Pharmacopoeia
(2010 version) listed 2,165 CHMs and their products. About
300 of them are commonly used in clinical practice, and many
others are used locally as folk medicines. In terms of the
literature on CHM, the theoretical aspects and practical experiences of several thousand years of usage are documented in
more than 8,000 books; the total number of ancient literature
about both CHM and TCM reached 13,000. Therefore, the
documentation of knowledge in CHM is unique in the world
(Table 1).
2.2. The Contribution of CHM to the World’s Pharmacy. CHM
has been influencing the world since ancient times. The
famous Italian traveler Marco Polo (1254–1324) described
a scene of merchants shipping Chinese herbs in Aden and
Alexandria in his Travel Book. During the sea voyage of Zheng
He between 1405 and 1433, China exported a large number
of herbs including rhubarb, angelica, velvet, poria, taurine,
ginseng, and cinnamon to other Southeast Asian countries.
In return, over the past 2,000 years, more than 40 kinds
of foreign herbs were imported into China and eventually
adopted by TCM; they include kelp from Korea, turmeric and
styrax from Southeast Asia, and others such as borneol, clove,
frankincense, myrrh, benzoin, senna, and saffron [35].
In the 18th century, with reference to Chinese ginseng,
Panax quinquefolium (also called American ginseng) was first
discovered. It is indigenous to the southern regions of Ontario
and Quebec in Canada and the midwestern, southern, and
eastern parts of the United States [36]. In recent decades,
studies have shown that American ginseng, like the Chinese

Animal
48
67
128
342
443
740
1,051
36

Mineral
21
46
87
253
161
82
114
18

Processing products

Formulae

>3,000
11,096

Other
63

194

172
1,384

47

one, also possesses neuroprotective, cardioprotective, antidiabetic, antioxidant, and anticancer properties, as well as the
ability to alleviate symptoms of the common cold [37, 38]. The
proven similarities between American ginseng and Chinese
ginseng have been instrumental in boosting the market of the
American product. From 1960 to 1992, both the demand and
the price for American ginseng increased, with the export
value being over US $104 million in 1992 in the USA alone.
During the period from 1997 to 2007, the average export
price of cultivated ginseng from the USA was US $19.30/lb
and that of wild ginseng was US $84.50/lb [39]. The Panax
family consists of at least nine species, including ginseng,
panax quinquefolium, panax notoginseng (Sanqi), and Panax
japonicus (Japanese ginseng) [40]. If Chinese ginseng had not
served as a reference herb, the Panax family would certainly
not have become so popular and might still be treated as
ordinary grass. Similarly, if the Chinese had not recognized
the medicinal value of bezoars (gallstones from cattle), they
would only have been treated as waste. Currently, China
imports more than 100,000 kilograms of gallstones each year,
about 60% of which comes from Africa, and the total value
amounts to US $100 million. A good quality gallstone sells
for between US $15 and 20 per gram [41].
In the winter of 753, Jian Zhen (688–763), a famous
Chinese master of Buddhism in the Tang Dynasty, arrived
in Nara, Japan, after several unsuccessful attempts, and he
brought with him a number of CHMs. To date, more than
60 kinds of CHMs are still kept in the Nara Shosoin.
According to the official body of Japanese kampo medicine
(the practice of CHM in Japan), 36 kinds of CHMs were
brought by Jian Zhen for use in Japan; they include ephedra,
asarum, peony, monkshood, polygalaceae, astragalus, licorice
root, angelica, bupleurum, Chuanxiong, scrophulariaceae,
scutellaria, platycodon, anemarrhena, pinellia, schisandra,
and eucommia [42]. To recognize the contribution of Jian
Zhen, he was renowned as the father of kampo medicine by
the Japanese. The 14th edition of the Japanese Pharmacopoeia
(JP), issued in 1993, listed 165 herbal ingredients, the majority
of Chinese origin, that are approved to be used in kampo
remedies [43]; the 16th Japanese Pharmacopoeia, published in
2012, listed 276 kinds of crude drugs (e.g., herbal medicines
and/or their extractions) [44].
All in all, the development of CHM has emerged from
thousands of years of Chinese civilization. It is therefore no
surprise that CHM is of great worth for mankind.
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2.3. Species in China and CHM. Nature has endowed China
with a vast landscape with varied geographical features and
a resultant wealth of medicinal plants. Geographically, China
(from south to north) covers equatorial, tropical, subtropical, warm-temperate, temperate, and cold-temperate zones.
Therefore, Chinese climatic conditions are suitable for the
growth and reproduction of various animals and plants. In
China, there are 499 kinds of mammals, 1,186 kinds of birds,
376 kinds of reptiles, 279 kinds of amphibians, and 2,084
kinds of fish, which account for 12.5, 13.1, 6.0, 7.0, and 12.1% of
their respective species in the world [45–50]. China has more
than 31,000 higher plants, 256 endemic genera, and 15,000–
18,000 endemic species (50–60% of the total on earth), many
of which are living fossils, such as dawn redwood (Metasequoia glyptostroboides Hu and Cheng), ginkgo (Ginkgo biloba
L.), silver fir (Cathaya argyrophylla Chun and kuang), and
tulip tree (Liriodendron chinense (Hemsl.) Sarg.) [51]. The
increasing demand for herbal products in the global market is
likely to challenge herbal resources in the world. In the China
Plant Red Data Book published in 1992, 388 species of plants
are listed as threatened, which include 121 as endangered
(i.e., first grade national protection), 110 as rare (second
grade national protection), and 157 as vulnerable (third
grade national protection). Among these plant species, 77 are
typical CHMs that account for 19.86% of the total threatened species [52]. Besides, 257 kinds of animal medicine
appear in the national key protection name list of wild
animals (Figure 1).
In CHM, there are 11,146 different kinds of plants, 1,581
kinds of animals/animal parts and insects, 80 kinds of
mineral drugs, and more than 50 kinds of crude chemical
preparations, as well as 5,000 (total one million) clinically
validated herbal formulations. Unlike other herbal medicines
and western medicines, CHMs are often prescribed as formulas under the guidance of TCM’s theories and practice. Each
herbal medicine prescription (formula, Fang-Ji in Chinese) is
a cocktail of many herbs tailored to the individual patient. It
allows us to blend herbs to enhance their positive effects and
reduce or eliminate any negative side effects they may have,
when they are used each alone (Figure 2).
Because of the differences in geographical and climatic
conditions, residents in various geographical regions in
China have distinctive lifestyles, customs, and cultures, as
well as disease spectra. These variations have brought about
the development of a wide variety of traditional medicine
practices. China has 56 ethnic groups, meaning that there
are 56 kinds of culture, language, and herbal medicine. CHM
(also called Han medicine) was developed by the Han ethnic
group. Table 2 shows the number of plant-derived herbal
medicines in various ethnic medicines as recorded in the
database of China plant species. In fact, the number of herbal
medicines is far bigger than that recorded in the database.
For example, Tibetan herbal drugs have 2,172 rather than
1,085 varieties, not including 214 kinds of animal drugs and
50 kinds of mineral drugs [53]. There is no doubt that
CHM, together with other ethnic herbal medicines in China,
comprises a gold mine of potential modern medicines and
health products.
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Table 2: Ethnic materia medica (EMM) in China.
Ethnic group
Han
Tibetan
Miao
Dai
Yi
Li-Su
Zhuang
Mongolian
Wa
Tu-Jia
Ha-Ni
De-Ang
A-Chang
Ji-Nuo
Du-Long
She
Mu-Lao
La-Hu
Uighur
Shui
Korean
Na-Xi
Bai
Mao-Nan
Pu-Mi
Bu-Lang
Bu-Yi
Beng-Long
Jing
Ge-Lao
Daur
Kazak
O-Lun-Chun
Hui
Manchu
Li
Yu-Gu
Gao-Shan
Tajik
Russian
Nu-Jiang
Wei-Xi
Total

EMMs
11,146
1,085
718
707
564
494
473
397
332
330
302
272
263
250
165
161
152
151
143
129
121
103
90
75
49
44
32
28
20
18
14
14
12
11
9
9
5
4
1
1
1
1
18,891

Data from “scientific database of China plant species. http://apps.searo
.who.int/PDS DOC”.

2.4. Pharmaceutics of CHM. Dosage form, also known as
routes of administration, is a mixture of components with
medicinal properties and nondrug components (excipient
or vehicle). It describes the physical form in which medication will be delivered into the body. Currently, there are
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More than 10 and 20 animal
species are considered extinct
and become endangered,
respectively.

Animal species
Grade I: 96 species
Grade II: 161 species
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There are 422 species threatened by
extinction, including 81 species of
mammals, 75 birds, 48 fishes, 31
reptiles, and 184 plants.

Protected species in China

488 kinds of
invasive alien
species (IAS)

Plant species
Grade I: 121 species
Grade II: 110 species
Grade III: 157 species

279 amphibian species

1,186 bird species

2,084 fish species
Species in China

28,000 marine species

499 mammal species
35,000 plant species

256 endemic genera

31,000 higher plants

15,000–18,000 species
of endemic species

Figure 1: Species and protected species in China.

more than 40 available dosage forms of CHM products
in the market. They include decoction (Tang-Ji, hot water
extract), tincture (Ting-Ji, ethanol extract), powders (SanJi, powder form), bolus/pills (Wan-Ji, boluses or small pills
containing herbal ingredients), pastes (Jin-Gao, extracts from
organic solvents), granules, tablets, oral liquids, and injection
liquids. Liniment, poultices, plasters, and ointments are
adopted for external use of CHM. Recently “nanomized”
and “aerosol” herbs have emerged as new dosage forms of
CHM [54–56].
Unlike synthetic drugs, CHMs are usually subjected to
specific treatments (processing, the process of preparing
CHM), also known as Pao-Zhi in Chinese, prior to use. PaoZhi is a very ancient part of the practice of Chinese medicine,
dating back at least 2,000 years. There are more than 30 kinds
of procedures involving stir-frying (Chao), calcining (Daun),
steaming (Zheng), boiling (Zhu), and so forth. The herbal
effects and compositions/ingredient structures are changed
after Pao-Zhi, as compared to the unprocessed version. Experience has shown that the effectiveness and security of some
CHMs are dependent upon their correct Pao-Zhi before being
used in clinic. This is one of the reasons why CHM is different
from the plant drug and/or natural drug. Regardless of the
primitive processing technology that was used in ancient

times, the rationale underlying the traditional processing of
CHM has been supported by scientific evidence in modern
research. Figure 3 shows the traditional processing methods
of CHM, together with their pharmaceutical processing
procedures, which are still employed in the pharmaceutical
industry of CMM in China [57].
2.5. The Status Quo of CHM. The CHM industry has always
been one of China’s traditional competitive industries. In
2010, CHM manufacturing assets in China exceeded 300
billion RMB, an increase of about 18%, nearly 5 percentage
points higher than the year before; the number of CMM
pharmaceutical enterprises amounts to more than 2,300, total
investment in fixed assets totaled nearly 500 billion RMB, an
increase of about 16% compared to the previous year [58].
As of today, there are 8,000 products related to CHM in the
China market. In 2010, China manufactured 2.384 million
tons of Chinese herbal products, with sales amounting to
417.875 billion RMB [59].
More than 8,000 varieties of CHMs or related herbal
products are now exported from China to more than 130
countries and regions worldwide; each year, more than 50
kind of CMMs are exported to the United States, including
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5,000 formulas in
common use in clinic

Statutory formula

Nonstatutory formula

Ancient formula

Empirical formula

Folk formula

Formula
(up to 1,000,000)

Modern formula

Mineral drugs
(80 species)

Animal medicines
(1,581 species)
CHMs
Plant medicines
(11,146 species)
Ethnic medicine
(4,000 species)

2,136 CHMs listed
in the 2010 Chinese
Pharmacopoeia

Crude chemicals
(up to 50 species)
Folk medicine
(7,000 species)

500-600 CHMs
in common use in clinic

Figure 2: Chinese herbal medicine (CHM) in China.

berberine, angelica, licorice, Fritillaria, turmeric, frankincense, Tianma, rhubarb, Eucommia, cloves, wolfberry, Panax,
fresh ginseng, and pinellia [60]. Over the past few years,
herbal exports have steadily increased from US $1.09 billion
in 2006 to US $1.46 billion in 2009 [61].
More importantly, in recent decades, China has put a
great deal of human efforts and financial resources to promote
research and development in the area of CHM in a systematic
manner, and this enormous effort is unmatched by other
traditional medicines around the world. In this context,
we have published reviews on the status of CHM research
and development as well as drug discovery in China [24].
In China, 3,563 extracts, 64,715 compositions, 5,000 single
compounds, and 130 kinds of CHM-related chemical drugs
have been developed [22]. From the marketing perspective,
currently, four models of application and five types of Chinese
herbal products can be adopted in the international arena.
The same approach may also be applied to other herbal
medicines (Figure 4).

3. Indian Herbal Medicine (IHM)
Indian
medicine/materia
medica/herbal
medicine
(IM/IMM/IHM), also called Ayurvedic medicine/materia medica (AYM/AYMM), belongs to the traditional
health care and longevity systems. Because the belief that

“everything can be a drug” is deeply rooted in Indian culture,
Ayurvedic physicians made use of an extensive collection of
medications, herbs/plants, even the urine of animals, and
described their effects meticulously. Currently, 70 percent of
Indians still rely on IM for their primary health care [66].
3.1. Literature Overview of IHM. In India, the history of using
plant resources for treating diseases can be dated back to
6,000 to 4,000 BCE, the Buddhist period. AYM has a vast
literature in Sanskrit and various Indian languages, covering
various aspects of diseases, therapeutics, and pharmacy.
The earliest references to such plants, minerals, and animal
products with their usage for medical purposes are found in
the Rig veda, an ancient Indian sacred collection of Vedic
Sanskrit hymns, and the Atharvaveda, the fourth and last
Veda of Hindu literature [67]. Bhava Prakasha, written by
Bhava-Mishra, is the most important text on herbs/plants and
is held in high esteem by modern Ayurvedic practitioners
[68–70].
The oldest text of AMM, the Rasa Vaisesika of Nagarjuna,
who is considered the most important Buddhist philosopher
after Buddha’s death [71], was composed during the 5th century CE. In this text the various concepts of drug composition
and action were described [72]. The Charaka Samhita is
the first recorded treatise fully devoted to the concepts and
practice of Ayurveda, with a primary focus on therapeutics

Evidence-Based Complementary and Alternative Medicine

7

Nanomized
herb

Injection liquid
Oral
liquid

Decoction
Tincture

Powders

Liniment

Ointment

Dosage forms

Plaster

Granule

Aerosol

Poultice
Tablet

Bolus

Pills

Paste

CHM

Pharmaceutical
techniques

Stir-frying

Boiling

Steaming

Calcining

With

With liquid additives
With
Yellow rice wine
Vinegar
Salt-water
Refined honey
Ginger juice
Refined suet

With solid additives
Without
additives

Bran
Rice
Sand
Fine powder of terra

Water
Salt-water
Medicinal juice
Vinegar
Yellow rice wine

Edible mother liquor
of mineral salt
preparation
Rhizoma zingiberis
recens and alumen

Figure 3: Dosage forms and pharmaceutical techniques in Chinese herbal medicine (CHM).

[73]. In the Charaka Samhita, plant-derived drugs are divided
into 50 groups according to their pharmacologic/therapeutic
actions. The next landmark in Ayurvedic literature was the
Sushruta Samhita. Although the text places special emphasis
on surgery, it also describes 395 medicinal plants, 57 drugs
of animal origin, and 64 minerals or metals as therapeutic
agents [74] (Figure 5). In ancient times, Ayurvedic texts were
very respected in the neighboring countries, and they were
also translated into Greek (300 BCE), Tibetan and Chinese
(300 CE), Persian and Arabic (700 CE), and so forth [75].
3.2. Plant Species in India and IHM. India possesses almost
8% of the estimated biodiversity of the world with around
126,000 species; there are about 400 families of flowering
plants in the world, at least 315 of these can be found in
India [79]. Currently, about 45,000 species (nearly 20% of the
global species) are found in the Indian subcontinent: ∼3,500
species of plants are of medicinal value; 500 medicinal plant
species are used by the contemporary Ayurvedic industry;
∼80% of the medicinal plant species are procured from wild
areas; and 10% of medicinal plants involved in active trade

are obtained from cultivation in farms [80]. The western
Himalayan region provides about 80% of herbal drugs in
Ayurveda, 46% of Unani, and 33% of allopathic systems [81];
50% of drugs recorded in the British Pharmacopoeia are
related to medicinal plants growing in this region [82].
In India, approximately 25,000 plant-based formulations
are used in traditional and folk medicines [83]. The number
of plant species used in various IM is as follows: Ayurveda,
2,000; Siddha (a type of ancient traditional Indian medicine),
1,300; Unani (a system of alternative medicine first developed
by the Islamic physician Avicenna in about 1025 CE), 1,000;
homeopathy, 800; Tibetan, 500; modern, 200, and folk, 4,500
[84]. More than 7,500 plant species are currently used in IM,
including tonics, antimalarials, antipyretics, aphrodisiacs,
expectorants, hepatoprotectants, antirheumatics, and diuretics [85, 86], as well as for the therapy of certain central
nervous system disorders [87, 88].
The IHMs are derived either from the whole plant or from
different organs, like leaves, stem, bark, root, flower, seed, and
so forth, but also include animals and minerals. Some drugs
are prepared from excretory plant products such as gum,
resins, and latex. Commonly used spices, herbs, and herbal
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Traditional model: decoction is made from a
mixture of crude herbs by extraction in boiling
water at home. This dosage form of CHMs is
commonly used in households and mainly
popular among the Chinese worldwide.

Modern model: different
dosage forms of CHMs such
as granule, tablet, and oral liquid
are manufactured by modern
pharmaceutical technology in
Japan and South Korea.

Quasi-chemical model: a mixture of active
constituents is extracted from herbs by modern
techniques. A good example is Ginkgo leave
extract which contains 24% ginkgo-ﬂavonol
glycosides and 6% terpene lactones.
Full-chemical model: single
compound is isolated from the
herbal materials or chemically
synthesized. Good examples
include artemisinin, taxol, and
arsenious acid.

Patterns

Exporting 260,000
tons in 2005

Importing about 7,735
tons annually

Global market
of CHM

Therapeutic herbal
products
(Zhong-Cheng-Yao in Chinese)
containing multiple herbs

Therapeutic herbal
products
(Zhong-Cheng-Yao in Chinese)
containing single herb

Products

Crude herbs
(Yin-Pian in Chinese)

Skin care and
cosmetics products
Health care
products

Figure 4: Styles of Chinese herbal medicine (CHM) in the global market (see also [62] of quasi-chemical model and [63–65] of full-chemical
model).

Paniyadi Varga liquids like water, milk,
alcohol, and urine

Over 500 ingredients

Iksukadi Varga sugar-cane, products of
sugar-cane juice and honey

Karpuradi Varga 84 aromatic ingredients

Dhanya Varga cereals corns and pulses
Dhanyaktannadi Varga food preparations

Saka Varga 56 plants used as vegetables

Suanadi Varga 44 metals and minerals

Mamsa Varga birds and animals meat
Misraka Varga anupana (post prandial drinks)
and other regimens

Vatadi Varga 50 ingredients

Rig Veda
(5000 BCE)
described 67 AMMs

Athara Veda
(4500-2500 BCE)
recorded 290 IHMs

Abhayadi Varga includes description of 165 drugs
Sunthyadi Varga 39 drugs

Materia medica of
Ayurveda
(2008 version)

Currently, 8,000 herbal
remedies are codified in
Ayurvedic medicine

Yajureda
(1000-600 BCE)
recorded 87 IHMs

Charaka Samhita
(∼ 900 BCE)
listed 526 IHMs

Phala Varga 56 edible fruits

Bhaa Prakasha
(1550)
described 470 IHMs

Sushruta Samhita
(∼ 600 BCE)
described 516 IHMs

Figure 5: Some important texts of Indian herbal medicine [76–78].
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species are used
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Figure 6: Plant species in India and Indian herbal medicine (IHM).

formulae are utilized for therapeutic interventions in about
28 kinds of chronic diseases in humans [89]. Special herbal
preparations, known as Rasayans, are used for rejuvenation
and retarding the aging process, thereby promoting longevity
[90].
Of the 700 plant species commonly used in the Indian
herbal industry, 90% of them are collected from the wild.
About 50% of the tropical forests, the treasure house of plant,
and animal diversity have already been destroyed. Many
valuable medicinal plants are on the verge of extinction. The
Red Data Book of India in 1997 has 427 entries of endangered
species of which 28 are considered extinct, 124 endangered, 81
vulnerable, 100 rare, and 34 insufficiently known species [91].
The Red Data Book of India released in 2012 described 3,947
species as “critically endangered”, 5,766 as “endangered”, and
more than 10,000 species as “vulnerable” [92] (Figure 6).
3.3. Pharmaceutics of IHM. Compared to those of CMM,
AYM possesses very complex formulae consisting of 30 or
more ingredients. In the formula, a number of ingredients,

which are properly processed for pharmaceutical application,
are chosen to balance the three humoral doctrines (“Vata”,
“Pitta,” and “Kapha”). Herbs used in AYM include essential
oils extracted from plants, fruits, vegetables, and common
spices. The crude herbal material may be ground into powders and put into capsules, cooked into teas, used topically,
taken raw, and so forth. IMM preparations on the market
and/or Ayurvedic medical practice are complex mixtures
including plant- and animal-derived products, minerals, and
metals, as well as involving several specific preparatory steps
or manufacturing processes.
Kasthoushadhies (herbal preparations) and Rasaoushadhies (herbo-bio-mineral-metallic preparations) are the two
major groups of IMM preparations [93]. The latter has a
metallic base but ordinarily does not contain active metal,
since the metal is converted into an ash or oxide and forms
an organometallic compound with a number of organic
materials used for trituration as Bhavana Dravya [94, 95].
Medicinal principles are present in different parts of the
plant such as root, stem, bark, heartwood, leaf, flower, fruit,
or plant exudates. Generally, the herbal remedies can be
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in various crude dosage forms like pills, powders, essential
oil, infusions, or poultices. AYM believes that Sandhana
kalpana (biomedical fermented formulations), a unique and
complex dosage form containing acidic and alcoholic fermented components, is one of the most effective dosage
forms of Ayurveda in practice for thousands of years [96].
During the fermentation process of liquid basic drugs, such
as juices or decoctions, alcohol is produced by in-source
material used in pharmaceutical procedure. Thus, extraction
of active principles of the herbal drugs is done through
self-generated alcohol. This formulation has longer shelf
life, quick absorption and action, and excellent therapeutic
efficacy as compared to other preparations [97].
The specific media are usually used in the manufacturing
process of IMM products according to the different preparation. This plays a very important role in either breaking down
the chemical compound(s) that is not required or forming the
novel active ingredient(s) that is of value to the people, for
example, Shodhana (purification/potentiation) of particular
poisonous herbs, like Gomutra (cow’s urine) for Shodhana
of Vatsanabha (Aconitum ferox Wall.) and Godugdha (cow’s
milk) for kupeelu (Strychnos nux-vomica Linn.) [98]. On the
other hand, Ayurvedic drugs are usually administered orally
along with vehicle materials (Anupana) such as honey, sugar,
jaggery, ghee, milk, warm water, and juice of some medicinal
herbs. These Ayurvedic Anupana (i.e., drug vehicles serving
as a medium of administration) can improve acceptability
and palatability and help in absorption of the main herbal
remedy; moreover, they may also act as an early antidote
(Figure 7).

India not only has a great role to play as a supplier of
herbal products for the domestic market, but it can also
benefit from the tremendous potential afforded by overseas
markets. Currently, the Indian herbal market is valued at
70 billion Rs., and over 36 billion Rs. worth of raw herbal
materials and herbal products is exported [106]. The export
of crude herbal extracts amounted to US $80 million, and the
total sales of herbal products added up to US $1 billion [107].
Among the exported herbal products, 60% are processed
plant materials that are unique to India, 30% are plant
extracts, and 10% are Ayurvedic preparations [108]. The
plant-derived pharmaceuticals exported from India include
isabgol, opium alkaloids, senna derivatives, vinca extract,
cinchona alkaloids, ipecac root alkaloids, solasodine, diosgenin/16DPA, menthol, gudmar herb, mehdi leaves, papian,
rauwolfia guar gum, jasmine oil, agar wood oil, and sandal
wood oil [109]. However, the export of 29 medicinal plants,
including plant parts and their derivatives/extracts, obtained
from wild sources, is prohibited by the Indian government
[109]. Indian herbal medicine has now become a rich source
of innovative drug discovery [110].
In India, the turnover of IHM industry is estimated to
be more than 88 billion Rs; the domestic market is of the
order of 40 billion Rs with a total consumption of all IMMs
to a figure of 177,000 metric tons (MT). India has 9,493 HM
manufacturing units, but 8,000 of them are small scale, one
having an annual turnover of less than 10 million Rs. Some
of the well-known units (with an annual turnover of more
than 500 million Rs.) include Dabur, Zandu, Himalaya, Shree
Baidyanath, and Arya Vaidya. They consume about 35% of the
total raw IHMs [111].

3.4. The Status Quo of IHM. The treatment of disease by
Ayurveda is highly individualized and depends on the psychophysiologic status of the patient, particularly in relation
to the season of the year [101]. Currently, more than 600
herbal formulas and 250 single plant drugs are included in the
“Pharmacy” of Ayurvedic treatments [102]; about 1,000 single
herbal remedies and 3,000 compound herbal formulations
are registered in India. More than 600 herbal formulae and
250 single plants are included in the “Pharmacy” of Ayurvedic
treatment [103]. The 6th Indian Pharmacopeia released in
2010 recognized 55 crude herbal drugs, 26 extracts, 3 finished
formulations, and 2 pharmaceutical aids that are marketed
[104].
According to a study commissioned by the Associated
Chamber of Commerce and Industry, the Indian herbal
industry is projected to double to 150 billion Rs. by 2015, from
the current 75 billion business [105]. In the 1990s, the annual
sales of the Indian herbal industry were about 23 billion
Rs. (as compared to 145 billion Rs. in the pharmaceutical
industry), with a growth rate of 15% [106]. By the end of
2012, the domestic market is expected to reach 145 billion Rs.
and the export market 90 billion Rs., with compound annual
growth rates of 20 and 25%, respectively [105]. The export
market for medicinal plants appears to be growing faster than
the Indian domestic market.

4. Arabic Herbal Medicine (AHM)
It is well known that ancient Hippocratic-Greek medical
knowhow was adapted and improved by Arabian herbalists,
pharmacologists, chemists, and physicians in the Middle
Ages. Furthermore, the majority of Arabs are Muslims,
and Arabic culture and Islamic ideology are closely related.
As such, Arabic medicine/materia medica/herbal medicine
(AM/AMM/AHM) may also be called Greco-Arab or Islamic
medicine.
4.1. Achievements of AM. The Arabic world used to be the
center of scientific and medical knowledge for many centuries
(from 632 to 1258 CE) after the fall of the Roman Empire.
The Legacy of Islam (published in 1931; edited by the late Sir
Thomas Arnold and Alfred Guillaume) states, “Looking back
we may say that Islamic medicine and science reflected the
light of the Hellenic sun, when its day had fled, and that
they shone like a moon, illuminating the darkest night of the
European Middle Ages; that some bright stars lent their own
light, and that moon and stars alike faded at the dawn of a
new day: the Renaissance. Since they had their share in the
direction and introduction of that great movement, it may
reasonably be claimed that they are with us yet.” [112].
During the middle ages, AM contributed greatly to the
development of modern medicine and pharmacy in Europe.
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Figure 7: Dosage forms and pharmaceutical techniques in Indian herbal medicine (IHM) [99, 100].

For instance, the European pharmacopoeia relied on Muslim
writings and information therein until the late 19th century.
Despite the scarcity of medical knowledge in the Koran,
Arabs adopted the ancient medical practices that originated
from Mesopotamia, Greece, Rome, Persia, and India (or
even China) [113, 114]. In the early 11th century, Avicenna
(980–1037), a great philosopher and physician, incorporated
a number of Chinese herbal preparations in his book Pharmacopoeia. Ancient Arabs established their “Pharmacy” on
the basis of physicochemical techniques such as evaporation,
filtration, distillation, sublimation, and crystallization used in
“alchemy” which was invented by the Chinese [115].
Alchemy is the predecessor of chemical discipline that
led to the development of natural science in modern times.
Therefore, China is regarded as one of the key players in
advancing modern civilization, particularly in the area of
scientific methodology. It has been stated that if Greece was
the theoretical founder of modern civilization, the Qin/Han
dynasty in ancient China was the technical founder of

modern natural sciences. Alchemy was invented during the
period of Warring States in ancient China, but it vanished
for no apparent reason in the middle of the Tang Dynasty.
Nevertheless, the spirit of exploration of the ancient Chinese
is praise-worthy. Several inventions by Taoist alchemists, such
as cinnabar (Zhu-Sha), orpiment (Ci-Huang), and realgar
(Xiong-Huang) in CHM, particularly gunpowder, have had a
far-reaching impact on modern medicine and on the world
in general [115].
Although AM was at the forefront of medical knowledge
in Renaissance Europe of the 15th century, unlike CM and
IM, its herbal medicine was not well developed from the start.
The theory of AM is based on the “humours” of Hippocrates
and Galen. There were more “modern” than “traditional”
elements in AM; therefore, it played a pivotal role in the
early formation and development of modern medicine. AM
mainly integrated various herbal medicines and related technologies that originated from other countries and regions and
established the foundation for the development of medicine
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Introduced around 350 new plant species as medicinal herbs

Modern pharmaceutical industry

Figure 8: Achievements of Arabic medicine and pharmacy [118, 119].

and pharmacy in modern medicine [116, 117]. Therefore, AM
carried on the past heritage and opened up the future in the
history of the development of human medicine (Figure 8).
4.2. Past and Present of AHM. During the 8th century, Arabs
in the Baghdad region were the first in history to separate
medicine from pharmacological science. The world’s first
drug stores were established in the Arab world (Baghdad,
754 CE). The forms employed in that period are still used
in therapy, and some formulations of drugs can be found
in pharmacopoeias even today [120]. The earliest records
of herbs, which were written on clay tablets in cuneiform,
were from Mesopotamia (dating back to 2600 BCE). The
best known Egyptian pharmaceutical record is the Ebers
Papyrus (dating back to 1500 BCE), which documented some
700 herbal medicines (mostly from plants), with dosage
forms including gargles, snuffs, poultices, infusions, pills, and
ointments and vehicles using beer, milk, wine, and honey
[121].
Since the 8th century, the practice of AHM has been using
natural remedies, both organic (such as camel urine) and
inorganic types, for the prevention and treatment of diseases
[122]. Interestingly, pharmacological studies have revealed
that camel urine treatment caused a significant cytotoxic
effect on bone marrow cells in mice [123]. The Middle East

region is inhabited by more than 2,600 plant species, of which
more than 700 species are noted for their use as medicinal
herbs or botanical pesticides; however, only 200–250 plant
species are still in use in traditional Arab medicine for the
treatment of various diseases [124]. Plant species from the
western Mediterranean coastal region (from Alexandria to
Sallum, Egypt) comprise 230 species belonging to 48 families;
89% of the species had medicinal value, 62% of the species
were common, approximately 24.9% were occasional, and
13% were rare [118].
Until now, 236 plant species, 30 animal species, 29 organic
substances, and 9 materials of other or mixed origins are still
being used in treating human diseases and are sold or traded
in the Mediterranean region and/or in the global market
[124]. A survey of the plant species in the Mediterranean
region by ethnopharmacologists indicated that 250–290 plant
species are still in use [125, 126]. In Israel, 129 plant species
are used in AM for the treatment of various diseases.
Among these plants, there are 40 species used for treating
skin diseases, 27 species for treating digestive disorders, 22
species for treating liver diseases, 16 species for treating
respiratory diseases and coughing, 22 species for treating
various forms of cancer, and 9 species for weight loss and
lowering cholesterol [127]. However, more than 1,400 kinds
of herbal medicines were used by Islamic physicians during
the period of the Arab Empire (632–1258).
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Figure 9: Past and present of Arabic herbal medicine [130].

The dosage forms utilized in AHM include decoction,
infusion, oil, juice, syrup, roasted materials, fresh salads or
fruits, macerated plant parts, milky sap, poultice, and paste, of
which some formulations of herbal drugs are still used today
[128]. Although AHM is the first choice for many people
in dealing with ailments in the Middle East, most of the
herbalists (such as those in Jordan), who acquire the expertise
from their predecessors, are not properly trained in herbal
medicine [129] (Figure 9).
In contrast to CHM or IHM, the physical characteristics
of the herbal size, shape, color, texture, and taste traditionally
served as important criteria in their selection for therapeutic
purposes. For example, seeds with kidney shape are used for
treating kidney stones; roots shaped similar to the human
body or fruits that resemble human testicles are traditionally
used to stimulate sexual desire or treat sexual weakness; a
yellow decoction or juice obtained from herbal leaves is used
for treating jaundice and liver diseases [131, 132].

5. Discussion
In this section, two important issues related to herbal
medicine are discussed.
5.1. The Theoretical Advantages of Herbal Medicine. Due to
shortage of scientific evidence on the molecular mechanism
of herbs, it is often considered as only an alternative choice

to conventional drugs. Here, we attempt to describe the
feasibility and superiority of herbal medicine containing
complex and multicompounds as medication using logical
concepts in philosophy.
Currently, multidrug therapy or polypharmacy, also
known as multiple drug intake or cocktail treatment, which
involves therapeutic interventions using combinations of
drugs (herbal versus chemical, herbal versus herbal, and
chemical versus chemical) through pharmacokinetic and
pharmacodynamic pathways or both [133–136], is commonly
practiced in clinical situations. It is believed that multidrug
therapy produces beneficial effects that do not occur when
using each drug alone. Due to the additive and/or synergistic interactions among the drugs, or the suppression of
adverse effects, multidrug therapy appears to be effective in
treating diseases such as cancer, AIDS, malaria, diabetes,
hypertension, MRSA, and chronic diseases associated with
old age. Nevertheless adverse drug reaction (ADR), another
important public health problem, may be enhanced after multidrug combination treatment through not only drug-drug
interaction, but also herb-herb or drug-herb interaction [137,
138]. For example, as a monotherapy, St John’s wort extract has
an encouraging safety profile. However, in some cases, lifethreatening interactions were reported when used together
with other drugs [139]. Therefore, the possibility of drug-drug
interaction (DDI), including both beneficial effects and ADR,
has caused the FDA and European Medicines Agency (EMA)
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to encourage the industry to perform drug interaction studies
[140]. In the new postgenomic era DDI can be predicted
with the data from pharmacogenetic information which
may have an important implication for the development
of personalized medicine and drug R&D for clinic and
pharmaceutical industry, respectively [141].
More often than not, the pathogenesis of diseases is
related to multiple targets rather than a single target. Asai
et al. found that nonsteroidal anti-inflammatory drugs,
cholesterol-lowering statins, and 𝛽- or 𝛾-secretase inhibitors
can produce additive effects on the reduction of A𝛽-amyloid
levels in cultured neuronal cells [142]. Combination therapy
of PA-824-moxifloxacin and pyrazinamide can kill over 99%
of drug-sensitive and multidrug-resistant Mycobacterium
tuberculosis in patients with tuberculosis (TB) within 2 weeks.
However, at present, the treatment of patients with TB
or multidrug-resistant TB using conventional drug therapy
requires 6 or 18–24 months, respectively [143]. A polypill
containing amlodipine, losartan, hydrochlorothiazide, and
simvastatin produces a significant effect in preventing heart
attacks and strokes [144]. Liu Wei Di Huang Wan (Rehmannia
Six Formula), which is a well-known Chinese herbal formula
used for the treatment of 137 kinds of diseases in China,
consists of six Chinese herbs: Radix Rehmanniae nourishes
kidney Yin and essence (minute substances for supporting
life); Fructus Corni nourishes the liver/kidney and restrains
the leakage of the essence; Rhizoma Dioscoreae tonifies spleen
Yin and consolidates the essence; Rhizoma Alismatis promotes urination to prevent buildup of significant fluids; Poria
drains dampness from the spleen; Cortex Paeoniae clears liver
fire [145–147]. Therefore, the multitarget herbal formula can
produce a wide range of therapeutic effects.
Herbal formulations evolved from thousands of years of
experience in practicing herbal medicine. While therapeutic
interventions using multiple drugs in modern medicine are
based on an understanding of disease processes and drug
mechanisms, the use of multicomponent herbal formulae
(Fu-Fang in Chinese herbal medicine) is based on CM theory
and practical experience. Unlike using a single drug in
orthodox medicine, raw plant or plant extracts contain an
array of bioactive ingredients (a single plant contains 100–
1,000 compounds of 20–50 different structure types) that
can produce additive and/or synergistic actions [148]. The
multi-ingredient herbal drug/formula allows for a multitarget
interaction in treating diseases. For instance, the common
cold is a viral infectious disease of the upper respiratory
system, which primarily affects the nasal cavity. However,
cold symptoms typically include coughing, sore throat, runny
nose, headache, fever, and discomfort in the entire body. So
far, no single chemical entity can simultaneously alleviate all
clinical manifestations of common cold. Therefore a typical
over-the-counter cold remedy is composed of multiple drugs,
such as aspirin (A), phenacetin (P), and caffeine (C), in an
APC tablet.
One and one can add up to more than two. Therefore,
herbal treatment resembles a cocktail treatment or “magic
shrapnel” (multidrugs act on multiple targets) [149]. The
chemical compounds residing in an herbal drug or formulation work together within the body to maintain health and/or
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fight against diseases. The concept of synergism in modern
pharmacology encompasses two aspects: (1) pharmacodynamic synergy results from the enhancement of action when
multiple biologically active substances are directed at related
targets in a physiological system, which are often linked to the
pathogenesis of a disease and (2) pharmacokinetic synergy
can result from alterations in drug absorption, distribution,
metabolism, and/or elimination (Figure 10).
5.2. Resource Conservation in Herbal Medicine. Excessive
medical treatment and medication, including the consumption of herbal medications, is a global trend, especially in
developed countries. Countless facts have indicated that
herbal preparations or formulations can be used for the
treatment of many common as well as complex diseases for
all ages, with a minimum of adverse side effects compared to
conventional drugs. Together with the long history of their
use, plant-derived herbs and herbal products are gaining
popularity in the global market as registered drugs, dietary
supplements, health care products, cosmetics, and so forth.
Medicinal plants are highly esteemed as a rich source of
new therapeutic agents for the prevention and treatment of
diseases. Nowadays, the public acceptance of herbal medicine
increases not only in Asian countries (49% in Japan, 45%
in Singapore, 70% in China, and 80% in India), but also in
western countries [150]. The sales of herbal drugs or related
products are expected to increase at an annual rate of 6.4%.
In the USA, the use of herbal products by consumers was
less than 5% in 1991, but it increased to 50% in 2004, and
the amount of botanical remedies constitutes as much as 25%
of total medications. According to a WHO report, the global
market value of herbal products to date is US $61 billion, but it
is predicted to grow to US $5 trillion by 2050 [151]. The market
shares in Europe and the USA are 41 and 20%, respectively
[152].
Of the 250,000 higher plant species on earth, more than
80,000 are of medicinal value even in the genome era. In
Brazil, it is estimated that there are almost 55,000 native
species, at least 1,200 documented medicinal plants, and
probably many more undocumented species used by various
indigenous groups [153]. It can be expected that natural
medicines, particularly herbal medicine, will make a growing
or even a decisive contribution to human health care again. By
2001, researchers had identified 122 compounds used in modern medicine which were derived from plant/herb sources.
Of these, 80% have an ethnic medical use which is identical
or related to the current use of the active component(s) of
the plant [154]. Some of these compounds include tubocurarine, morphine, codeine, aspirin, atropine, pilocarpine,
ephedrine, vinblastine, vincristine, taxol, podophyllotoxin,
camptothecin, digitoxigenin, gitoxigenin, digoxigenin, capsaicin, allicin, curcumin, and artemisinin. Unfortunately,
many plant species on earth have become endangered as
the consumption of herbs and herbal products continues to
increase world-wide.
Traditional herbal medicine uses remedies derived from
plants, animals, metals, and minerals. If herbal resources
are inappropriately exploited, the extinction of many plant
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Figure 10: Pharmacodynamic synergism and pharmacokinetic synergism of herbal medicines.

species will inevitably occur, with a resulting adverse alteration of the ecological environment. For example, for more
than 30 years wild Panax notoginseng has no longer been
found in Yunnan province (the origin of the plant) in China
[155]; the acquisition of one kilogram of wild licorice will
destroy 8–10 acres of grasslands [156]; digging of one Cordyceps can cause direct damage to about 30 cm2 of grassland
[157]. To treasure and maintain the gifts from mother nature
(Hindu philosophy regards the Earth as a living being, i.e.,
mother nature), governments should install measures to
ensure the ethical exploitation of herbal resources in their
countries or societies. Therefore, it is high time to formulate
strategies to avoid the overexploitation of herbal resources.

6. Concluding Remarks
Since ancient times, disease has been a leading cause of
morbidity/mortality, and it is associated with a heavy economic burden among people with diseases. Despite current
advances in science and medicine, disease remains a serious
threat to public health in both developed and developing
countries, urban and rural areas, and all ethnic groups.
Ancient and modern people take medicines to fight illness or to feel better when they are sick. Most medicines
(conventional drugs) at present are chemically synthesized

and some are isolated from naturally occurring plants on
the basis of their use in traditional medicine. However,
our ancestors took only certain kinds of specific natural
remedies to fight or prevent a specific illness. Because modern
drug development is a high-risk (and therefore high-failure)
commercial endeavor and synthetic drugs have a high rate
of adverse events; there is a universal trend of using herbal
medications or related products.
Based on cultures and geographical regions, various kinds
of herbal remedies have evolved. Herbal medicines are therefore an integral part of culture and geographical environment,
and various kinds of herbal medicines have their own unique
way of understanding and treating a disease. However, the
globalization of trade and market has brought about an
integration of different kinds of herbal medicines over the
world. At present, herbal medications or related products in
the global market are derived from Chinese herbs, Indian
herbs, Arabic herbs, and Western herbs. Herbal remedies
may also be classified into three categories, namely, modern
herbs, theoretical herbs, and empirical herbs, in accordance
with their nature/characteristics and the nature of current
usage [158]. As for the medications derived from herbs,
they no longer belong to any herbal series or category and
have essentially become equivalent to conventional drugs.
In general, most herbal remedies/formulae are considered
to be safe and are well tolerated because they have been
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Herbs have been
modified in their shape,
dosage form, methods
of preparation, or
medical indications.

Herbs have been used for a long time and are well documented with
their special theories/concepts and are duly accepted by country
such as Chinese herbs and Indian herbs.
Herbs are historically and
freely used in local
community or region.

Category 1: theoretical herbs

Category 2: modern herbs

It is used based on herbalists’ clinical
experience or intuition. The herbal
knowledge is preserved by folk
healers via oral tradition such
as European and Native American herbs.

Western herbology

Currently, it is the most
inﬂuential herbal
remedies in the world.

Category 3: empirical herbs

Based on property

HM classification

In the middle ages, Arabians adopted
and improved the ancient medicinal
practices of Mesopotamia, Greece,
Rome, Persia, and India.

Based on region

Chinese herbology

Indian herbology

Arabic herbology

It is the oldest
healthcare system
in the world.

Figure 11: Classification of herbal medicines (HMs) in the international market.

successfully used for thousands of years as foods to promote
health and as medicines to treat diseases. To date, herbal
products are widely available to consumers and have become
increasingly popular throughout the world. There is no doubt
that herbal products will continue to play a crucial role in the
health care system of human societies, not to mention that
secondary metabolites of plants are economically important
as drugs, fragrances, pigments, food additives, and pesticides
(Figure 11) [159].
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